Navigation Links
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Date:6/24/2008

guide-lines for diagnosis and treatment of skin cancer, and it provides direction, coordination and organizations of clinical, therapeutic, and experimental trials.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
2. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Genta Clinical Programs Featured at American Society of Hematology Meeting
11. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and Markets has announced the addition of the "Hematology ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 The ... in developed countries; however, it is expected to witness high growth ... India , and Brazil in ... analyzers and reagents market is driven by factors such as increasing ...
(Date:7/30/2014)... Research and Markets has announced ... Packaging Industry Report 2014" report to their offering. ... The Global and Chinese Aseptic Packaging Industry Report is ... of the global Aseptic Packaging industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
(Date:7/30/2014)... 2014   Unique Pizza and Subs Corporation ... UPZS), a Delaware Corporation, is pleased to announce ... Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical company that produces ... US-based Larasan will work with Unique to help ... Larasan,s vast distribution network throughout China ...
Breaking Medicine Technology:Hematology Analyzers & Reagents Market - Forecasts to 2019 2Global and Chinese Aseptic Packaging Industry Report 2014 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3
... COUNTY, Calif., Nov. 18, 2010 Beckman Coulter, Inc. ... and marketer of products that simplify, automate, and innovate ... Coulter,s senior vice president corporate strategy, will present at ... Care Conference on Wednesday, December 1, 2010 at 12:30pm ...
... Nov. 18, 2010 NeoStem, Inc. (NYSE Amex: ... with operations in the U.S. and China, today announced that ... at the 2010 Maxim Group Growth Conference this morning and ... events will be held in New York, NY. ...
Cached Medicine Technology:Beckman Coulter to Present at the Piper Jaffray 22nd Annual 'Unplugged' Health Care Conference 2NeoStem to Present at Two Investor Conferences Thursday, November 18, 2010 2NeoStem to Present at Two Investor Conferences Thursday, November 18, 2010 3
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... 30, 2014 Good Neighbor Community ... an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , In this ... Community Services’ vision to redefine the traditional approach ... dynamic services. Through passion, innovation, determination, excellence, and ...
(Date:7/30/2014)... It can happen in an instant: A small child pulls ... gets critically injured when the furniture tips over. "Every ... their homes and imagine what could tip over, fall off ... it becoming a reality," Dr. Alex Rosenau, president of the ... release. Between 2009 and 2011, roughly 43,000 people ended ...
(Date:7/30/2014)... to fuel cancer as well as evolutionary changes in ... that occur randomly throughout the genome. , However, recent ... formation of multiple mutations that arise simultaneously and in ... mutations are frequently found in regions where chromosomal rearrangements ... Cell Reports , may one day lead to ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2
... known that under normal conditions, the breast cancer protein BRCA1 ... just how BRCA1 moves to the damaged site and recruits ... , Now, a new study from the University of ... BRCA1 protein and their involvement in the DNA repair pathway, ...
... as Top Driver of Quality InitiativesHOLMDEL, N.J., March ... survey unveiled at the Interphex Conference in New ... impact on managers, day-to-day job functions or companies, ... of respondents - 81 percent - reported that ...
... Approximately 650,000 Children and 1,300,000 Adults Living in the ... DiseaseLINCOLNSHIRE, Ill., March 18 Senator Richard Durbin (D-IL) ... that, for the first time in history, will address ... (CHDs) - America,s most common birth defect that affects ...
... NAPLES, Fla., March 18 People who care for ... regularly participate in social media. More than 65 percent ... as their primary means of support and encouragement, according ... online forums and message boards, such as www.agingcare.com/community ...
... pharmaceutical and bio-sciences owner operators helps greatly ... facility in a validated stateHUNTSVILLE, Ala., March ... engineering software provider, introduced today SmartPlant(R) for ... the cost of construction and qualification/commissioning activities ...
... Codexis, Inc. today announced that Joseph Sarret, M.D., J.D., ... from his previous position as Vice President, Corporate Development. ... President and CEO. Dr. Sarret was named Vice ... in 2005 as Corporate Counsel and Director, Business Development. ...
Cached Medicine News:Health News:Penn researchers identify new protein important in breast cancer gene's role in DNA repair 2Health News:Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures 2Health News:Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures 3Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 2Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 3Health News:When Time is Limited, Internet is the Number One Support Tool for Caregivers 2Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 2Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 3Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 4Health News:Codexis Names Sarret SVP, Corporate Development 2
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless ...
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right; ) overall length 120mm; Stainless ...
0.12 1x2 tips on a 2.5mm platform; Stainless Steel Tip; 32mm shaft; Titanium Handle....
4 Gently Curved, Prongs, 5mm Extended, Stainless Steel Tip; with Titanium Handle....
Medicine Products: